Cold Agglutinin Disease Cad Epidemiology Forecast

DelveInsight's "Cold Agglutinin Disease (CAD) - Epidemiology Forecast-2032" report delivers an in-depth understanding of the Cold Agglutinin Disease, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019-2032

Cold Agglutinin Disease (CAD) Understanding

The DelveInsight’s Cold Agglutinin Disease epidemiology report gives a thorough understanding of the Cold Agglutinin Disease by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis.

 

Cold Agglutinin Disease (CAD), is a rare autoimmune disorder characterized by the pre-mature destruction of red blood cells (hemolysis). Autoimmune diseases occur when one’s own immune system attacks healthy tissue. More specifically, CAD is a subtype of autoimmune hemolytic anemia. Autoimmune hemolytic anemia (AIHAs) are clinic-pathological entities characterized by the production of autoantibodies directed against surface antigens on red blood cells (RBCs). AIHAs are generally classified as warm, cold, or mixed type, depending on the optimum temperature at which the autoantibodies bind surface antigens. In this type of disorder, red blood cells are “tagged” by antibodies and are then destroyed by other types of immune cells. The disease is termed “cold” because the antibodies are active and cause hemolysis at cold temperatures, usually 3 to 4oC (37 to 39oF), which is not necessarily the case in other types of autoimmune hemolytic anemia.

 

CAD can be divided into two types: primary and secondary CAD, The types are based on the disorder’s underlying cause. In both, the immune attack is mediated by antibodies, called cold agglutinins, which bind to red blood cells, causing them to clump together and, ultimately, die.

 

Diagnosis

The diagnosis of hemolytic anemia may be suspected based on a thorough clinical evaluation, a detailed patient history, identification of characteristic symptoms and a variety of tests such as blood tests that measure values of hemoglobin and the percentage of the total blood volume occupied by red blood cells (hematocrit). Blood tests may also show an elevated value of immature red blood cells (reticulocytes), which occurs when the body is forced to produce extra red blood cells to make up for those that are destroyed prematurely. Some individuals with hemolytic anemia have elevated values of bilirubin in the blood (hyperbilirubinemia).

 

In CAD, the immunoglobulin may not be picked up with the Coombs test, but this test most often picks-up the presence of C3 on the red cells, A thermal amplitude test then has to be performed to measure the reactivity of the detected antibodies at different temperatures. It is important to know how much of this cold agglutinin is present in each patient, especially to determine how it changes with treatment. This is done by determining the titer for the cold agglutinin, which is done by progressively diluting the serum of the patient until the agglutination of the red cells disappears.

 

After a diagnosis of CAD is made, patients should be evaluated to attempt to identify a possible underlying condition such as an infection, autoimmune disease, or another blood disorder. The tests that will be performed depend on the clinical situation and the affected individual. In summary, the following sequence allows the diagnosis of CAD: 1) detection of anemia, 2) determination that the anemia is caused by hemolysis, based on elevated bilirubin and LDH and low haptoglobin, 3) determination that CAD is the cause of hemolytic anemia with a Coombs test and a cold agglutinin titer, and 4) investigation for a secondary cause of CAD.

Cold Agglutinin Disease (CAD) Epidemiology

The Cold Agglutinin Disease epidemiology section provide insights about historical and current Cold Agglutinin Disease patient pool and forecasted trend for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

 

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Cold Agglutinin Disease epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

  • In the year 2021, the total prevalent cases of Cold Agglutinin Disease was 12,815 cases in the 7MM which are expected to grow during the study period, i.e., 2019–2032.
  • The disease epidemiology covered in the report provides historical as well as forecasted Cold Agglutinin Disease epidemiology [segmented as Total Prevalent Cases of Cold Agglutinin Disease, Total Diagnosed Cases of Cold Agglutinin Disease, Total Gender-specific Cases of Cold Agglutinin Disease, Total Type-specific Cases of Cold Agglutinin Disease, and Total Treated Cases of Cold Agglutinin Disease] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Country Wise - Cold Agglutinin Disease (CAD) Epidemiology

The epidemiology segment also provides the Cold Agglutinin Disease epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Cold Agglutinin Disease domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Cold Agglutinin Disease market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Scope of the Report

  • The report covers the descriptive overview of Cold Agglutinin Disease, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies.
  • Comprehensive insight has been provided into the Cold Agglutinin Disease epidemiology and treatment in the 7MM.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Cold Agglutinin Disease are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of Cold Agglutinin Disease market; historical and forecasted is included in the report, covering drug outreach in the 7MM.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Cold Agglutinin Disease market.

Report Highlights

  • In the coming years, Cold Agglutinin Disease market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Cold Agglutinin Disease R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Cold Agglutinin Disease. Launch of emerging therapies will significantly impact the Cold Agglutinin Disease market.
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Cold Agglutinin Disease.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Cold Agglutinin Disease (CAD) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Cold Agglutinin Disease Pipeline Analysis
  • Cold Agglutinin Disease Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Cold Agglutinin Disease (CAD) Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Cold Agglutinin Disease Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Cold Agglutinin Disease (CAD) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Epidemiology Insights:

  • What is the disease risk, burden and regional/ethnic differences of the Cold Agglutinin Disease?
  • What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What is the historical Cold Agglutinin Disease patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Cold Agglutinin Disease in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • Where will be the growth opportunities in the 7MM with respect to the patient population pertaining to Cold Agglutinin Disease?
  • Out of all 7MM countries, which country would have the highest prevalent population of Cold Agglutinin Disease during the forecast period (2019-2032)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Cold Agglutinin Disease market
  • To understand the future market competition in the Cold Agglutinin Disease market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Cold Agglutinin Disease in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Cold Agglutinin Disease market
  • To understand the future market competition in the Cold Agglutinin Disease market

1. Key Insights

2. Report Introduction

3. Cold Agglutinin Disease (CAD) Market Overview at a Glance

3.1. Market Share (%) Distribution of CAD in 2019

3.2. Market Share (%) Distribution of CAD in 2032

4. Executive Summary of Cold Agglutinin Disease (CAD)

4.1. Key Events

5. Epidemiology and Market Methodology

6. Disease Background and Overview

6.1. Introduction

6.2. Causes of CAD

6.3. Signs and symptoms of CAD

6.4. Complications of CAD

6.5. Clinical Manifestations of CAD

6.6. Pathophysiology of CAD

6.7. Pathogenesis of CAD

7. Diagnosis of Cold Agglutinin Disease (CAD)

7.1. Diagnostic Algorithm

7.2. Diagnosis Tests

7.2.1. Physical Examination

7.2.2. Imaging technique

7.2.3. Laboratory tests

7.3. Differential Diagnosis

8. Diagnostic Guidelines

8.1. First International Consensus Meeting (2019) recommendations for diagnosis of CAD

8.2. European British Committee for Standards in Haematology (BCSH) recommendations for diagnosis of CAD

9. Treatment of Cold Agglutinin Disease (CAD)

9.1. Treatment Algorithm of CAD

10. Treatment Guidelines

10.1. European British Committee for Standards in Hematology (BCSH) recommendations for treatment of CAD

10.2. First International Consensus Meeting (2019) recommendations for treatment of CAD

11. Epidemiology and Patient Population

11.1. Key Findings

11.2. Epidemiology of Cold Agglutinin Disease (CAD)

11.3. Epidemiology Scenario

11.3.1. Total Prevalent Cases of Cold Agglutinin Disease (CAD)

11.3.2. Total Diagnosed Cases of Cold Agglutinin Disease (CAD)

11.3.3. Total Gender-specific Cases of Cold Agglutinin Disease (CAD)

11.3.4. Total Type-specific Cases of Cold Agglutinin Disease (CAD)

11.3.5. Total Treated Cases of Cold Agglutinin Disease (CAD)

12. KOL Views

13. Unmet Needs

14. Appendix

14.1. Bibliography

14.2. Report Methodology

15. DelveInsight Capabilities

16. Disclaimer

17. About DelveInsight

List of Tables

Table 1: Summary of Cold Agglutinin Disease, Market, Epidemiology, and Key Events (2019–2032)

Table 2: Total Prevalent Cases of Cold Agglutinin Disease (CAD) (2019–2032)

Table 3: Total Diagnosed Cases of Cold Agglutinin Disease (CAD) (2019–2032)

Table 4: Total Gender-specific Cases of Cold Agglutinin Disease (CAD) (2019–2032)

Table 5: Total Type-specific Cases of Cold Agglutinin Disease (CAD) (2019–2032)

Table 6: Total Treated Cases of Cold Agglutinin Disease (CAD) (2019–2032)

List of Figures

Figure 1: Epidemiology and Market Methodology

Figure 2: Antibody-Mediated Hemolysis

Figure 3: Signs and Symptoms of CAD

Figure 4: Pathophysiology of CAD

Figure 5: Diagnostic algorithm for CAD

Figure 6: Typical acrocyanosis exacerbated by cold exposure

Figure 7: Diagnostic test using Nailfold capillaroscopy

Figure 8: Pharmacological management of CAD

Figure 9: Treatment Algorithm of CAD

Figure 10: Total Prevalent Cases of Cold Agglutinin Disease (CAD) in the 7MM (2019–2032)

Figure 11: Total Diagnosed Cases of Cold Agglutinin Disease (CAD) in the 7MM (2019–2032)

Figure 12: Total Gender-specific Cases of Cold Agglutinin Disease (CAD) in the 7MM (2019–2032)

Figure 13: Total Type-specific Cases of Cold Agglutinin Disease (CAD) in the 7MM (2019–2032)

Figure 14: Total Treated Cases of Cold Agglutinin Disease (CAD) in the 7MM (2019–2032)

 

Forward to Friend

Need A Quote